US Stock MarketDetailed Quotes
HOWL Werewolf Therapeutics
- 1.770
- -0.160-8.29%
Close Nov 15 16:00 ET
- 1.810
- +0.040+2.26%
Post 20:01 ET
78.88MMarket Cap-1164P/E (TTM)
1.970High1.755Low630.49KVolume1.950Open1.930Pre Close1.15MTurnover2.84%Turnover RatioLossP/E (Static)44.56MShares8.19452wk High0.88P/B39.33MFloat Cap1.66052wk Low--Dividend TTM22.22MShs Float23.990Historical High--Div YieldTTM11.14%Amplitude1.390Historical Low1.823Avg Price1Lot Size
Werewolf Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -72.89%-12.46M | -29.81%-14.18M | -54.55%-15.3M | 19.67%-32.61M | 61.37%-4.59M | 50.19%-7.21M | -3,504.29%-10.92M | 29.05%-9.9M | 5.32%-40.6M | 6.34%-11.87M |
| Net income from continuing operations | -101.24%-16.67M | -238.35%-17.25M | -35.14%-16.19M | 30.56%-37.37M | -0.61%-12M | 30.63%-8.29M | 65.07%-5.1M | 21.91%-11.98M | -7.66%-53.81M | 33.24%-11.93M |
| Operating gains losses | ---106K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --7K | ---- |
| Depreciation and amortization | 2.02%454K | 4.61%454K | 9.18%464K | 59.78%1.76M | 10.31%460K | 10.15%445K | 134.59%434K | 333.67%425K | 411.11%1.1M | 768.75%417K |
| Other non cash items | -0.48%623K | 18.09%483K | 176.47%468K | -59.43%878K | -29.57%455K | 112.20%626K | -51.31%409K | -259.79%-612K | 316.96%2.16M | 5,772.73%646K |
| Change In working capital | 158.78%1.23M | 106.85%589K | -1,536.20%-2.34M | -332.14%-5.89M | 256.84%4.63M | 59.51%-2.09M | -174.82%-8.6M | 119.54%163K | 11.51%2.54M | -176.85%-2.95M |
| -Change in receivables | -92.03%81K | 134.23%230K | -14.56%575K | 180.51%5.58M | 273.55%4.56M | 148.85%1.02M | 69.73%-672K | --673K | ---6.93M | ---2.63M |
| -Change in prepaid assets | 848.09%980K | -109.61%-1.18M | -50.60%704K | 583.59%1.27M | -82.94%535K | 80.51%-131K | 87.55%-562K | -20.35%1.43M | 91.47%-262K | 583.22%3.14M |
| -Change in payables and accrued expense | 137.38%849K | 163.37%2.48M | -373.42%-2.47M | -242.32%-4.34M | 211.72%953K | -1,050.21%-2.27M | -161.59%-3.92M | 133.38%903K | -51.42%3.05M | -122.61%-853K |
| -Change in other current liabilities | ---- | ---- | -50.30%-744K | ---- | ---- | ---- | ---- | ---495K | ---- | ---- |
| -Change in other working capital | 6.36%1.09M | 48.69%-2.02M | 82.63%-407K | -225.75%-8.4M | 13.09%-3.15M | 138.52%1.02M | -130.58%-3.94M | -2,957.32%-2.34M | 2,873.03%6.68M | -1,497.68%-3.62M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -72.89%-12.46M | -29.81%-14.18M | -54.55%-15.3M | 19.67%-32.61M | 61.37%-4.59M | 50.19%-7.21M | -3,504.29%-10.92M | 29.05%-9.9M | 5.32%-40.6M | 6.34%-11.87M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 98.64%-3K | 90.66%-17K | 33.93%-111K | 78.70%-769K | 61.78%-198K | 88.69%-221K | 83.62%-182K | -500.00%-168K | -625.10%-3.61M | -90.44%-518K |
| Net PPE purchase and sale | 98.64%-3K | 90.66%-17K | 33.93%-111K | 78.70%-769K | 61.78%-198K | 88.69%-221K | 83.62%-182K | -500.00%-168K | -625.10%-3.61M | -90.44%-518K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 98.64%-3K | 90.66%-17K | 33.93%-111K | 78.70%-769K | 61.78%-198K | 88.69%-221K | 83.62%-182K | -500.00%-168K | -625.10%-3.61M | -90.44%-518K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -114.63%-6K | -1,504.62%-9.72M | -58.33%20.26M | 267.34%58.43M | 622.37%9.07M | -99.63%41K | -79.74%692K | 30,480.50%48.62M | -85.46%15.91M | 3,205.26%1.26M |
| Net issuance payments of debt | --0 | ---10M | --0 | --40M | --0 | --0 | --0 | --40M | --0 | --0 |
| Net common stock issuance | -174.36%-29K | 36.60%877K | 134.80%20.25M | 16.45%18.33M | 821.86%9.03M | -99.65%39K | -82.43%642K | --8.62M | -85.90%15.74M | --979K |
| Proceeds from stock option exercised by employees | 1,050.00%23K | 52.00%76K | --12K | -60.63%100K | 100.00%48K | -97.14%2K | 4,900.00%50K | --0 | 23.90%254K | -7.69%24K |
| Net other financing activities | --0 | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 96.30%-88K | 2,008.33%253K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -114.63%-6K | -1,504.62%-9.72M | -58.33%20.26M | 267.34%58.43M | 622.37%9.07M | -99.63%41K | -79.74%692K | 30,480.50%48.62M | -85.46%15.91M | 3,205.26%1.26M |
| Net cash flow | ||||||||||
| Beginning cash position | -13.97%136.51M | -5.12%160.43M | 19.19%155.58M | -17.82%130.53M | 6.80%151.29M | 7.93%158.68M | 16.60%169.09M | -17.82%130.53M | 71.20%158.83M | -17.51%141.66M |
| Current changes in cash | -68.80%-12.47M | -129.70%-23.91M | -87.42%4.85M | 188.51%25.05M | 138.54%4.29M | -38.09%-7.39M | -620.29%-10.41M | 378.99%38.56M | -142.85%-28.3M | 13.75%-11.13M |
| End cash Position | -18.01%124.04M | -13.97%136.51M | -5.12%160.43M | 19.19%155.58M | 19.19%155.58M | 6.80%151.29M | 7.93%158.68M | 16.60%169.09M | -17.82%130.53M | -17.82%130.53M |
| Free cash flow | -67.79%-12.47M | -27.84%-14.19M | -53.07%-15.41M | 24.49%-33.38M | 61.39%-4.78M | 54.77%-7.43M | -685.22%-11.1M | 27.99%-10.07M | -1.92%-44.21M | 4.30%-12.39M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data